ABK Biomedical Leadership Team
President and CEO
Mike Mangano is an accomplished global executive leader with over 25 years’ experience in the medical device industry. Over this time, he served as a member of senior leadership and executive committees and has a long history of success in building dynamic teams, leading organizational change, creating and shaping strategies, and executing programs leading directly to increased shareholder value. These accomplishments include his recent role as CEO of ReShape Medical, and his success in growing Sirtex Medical, an Interventional Oncology medical device manufacturer, from $34 million in revenue to over $130 million, during his six-year term as President of the Americas.
Prior to his role at Sirtex Medical, Mike served 15 years at Boston Scientific, where he functioned in many key roles and most recently as Director of International Distribution Management. Mike brings pragmatic leadership to ABK with his vast experience in sales/marketing management, product development, strategic planning, international business, M&A, project management, and business model development. His experience and guidance will help take ABK Biomedical to the next level in delivering commercial excellence for our customers and the patients that will benefit from our innovative products.
Chief Business Officer
Gary Donofrio brings extensive marketing and commercialization experience to ABK, with over 25 years in the medical device field, including Sirtex Medical and Boston Scientific.
Before joining the ABK Biomedical Leadership Team in 2018, Gary spent over seven years at Sirtex Medical, a global therapeutic oncology/medical device company, most recently as Senior Vice President, overseeing Marketing and Health Economics functions, and General Manager of the Latin America business unit. He started his career at Sirtex as Director of US marketing, where he managed all the marketing functions, including strategic planning, market development, conference management, KOL development, product commercialization, new business development (merger/partner assessment), and the sales force. He moved to Vice President, Marketing and then to Vice President, Americas Marketing and General Manager, Latin America, before becoming Senior Vice President. Gary also spent 17 years with Boston Scientific, Endoscopy, leading sales, marketing and commercialization functions.
Gary has multiple achievement awards & accomplishments in sales, sales training, region sales management, global product management, global marketing management, e-marketing management, and market development management.
Chief Financial Officer
Mike Tyson has extensive history and financial capabilities, including over 35 years’ experience in public accounting and leadership positions with Allergan, Abbott Medical Optics (AMO) and six years with VC-backed AqueSys, Inc.
Mike began his career working at Price Waterhouse Cooper, where he achieved his CPA designation. Mike then joined Allergan, where he spent 12 years, initially in their Corporate Accounting & SEC reporting group. He then moved overseas as Director of Finance in Puerto Rico, and finally lead Allergan’s North American Accounting Operations. Mike joined ophthalmic medic device-maker AMO upon their spin-off from Allergan in 2002 and was appointed VP of Finance. There he set up the finance operation, headed finance for all their divisions, both domestic and international, and integrated key acquisitions. Mike was recruited by AqueSys, Inc. in 2010 to become VP of Finance & Operations. In October 2015 the company was acquired by Allergan in a highly successful, $300/$725 million exit. Most recently Mike has consulted with start-ups in the Orange County area, including ReShape Lifesciences and Fresca Medical.
Mike is responsible for ABK’s Finance, HR, and IT functions.
VP R&D and Nuclear Operations
Marc Gregoire is an accomplished professional mechanical engineer with extensive experience in in the nuclear medical products sector. Throughout his over 25 year career, he has held several leadership positions directing the development, engineering and realization of radioactive medical devices and radiopharmaceuticals and manufacturing facilities in a complex regulated environment.
Marc spent almost 20 years with Nordion Inc., working on radiopharmaceutical products and manufacturing facilities including Yttrium-90 and Indium-111 parenteral solutions, Y-90 implantable microspheres, Cobalt-60 external beam therapy machines and product delivery systems. During his tenure at Nordion, Marc also held prominent roles in package engineering, quality assurance, operations and strategic supply management.
After Nordion, Marc spent four years developing a successful professional consulting practice working with multinational corporations, governments, and healthcare institutions as Director of Versant Solutions Inc. before joining ABK.
As a member of the ABK Biomedical Leadership Team, Marc is responsible for R&D, product engineering, and manufacturing operations.
VP of Clinical Development and Regulatory Affairs
David Dobrowski is an accomplished Life Sciences Executive and Enterprise Leader with over 25 years of pharmaceutical and medical device development experience. He has shepherded numerous new products through development and commercialization and has successfully executed more than a dozen FDA new product approvals, with a 100% success approval rate for 510k, NDA, BLA, and PMA submissions.
David most recently worked at Merz where he started as Head of Regulatory Affairs and Product Safety in 2011. He was promoted to VP of R&D, responsible for Clinical Affairs & Operations, Scientific Affairs, Project Mgmt., NBD Integration, Product Safety, Medical Writing, and Regulatory. David was part of the Executive Leadership Team, managed a team of over 50 people, and was the recipient of CEO’s Business Excellence President’s Club award in 2015. Prior to joining Merz David shaped his career with roles of increasing responsibility at Salix Pharmaceuticals, UCB / Schwarz Biosciences, Wyeth, and Novartis.
David will be responsible for the development/management of ABK’s clinical programs and regulatory strategy/execution. He will also oversee the quality function.
Co-Founder and Chief Medical Officer
Dr. Bob Abraham has spent more than 25 years as a practicing clinician and interventional radiologist (IR) at the QEII Health Sciences Center. He earned his medical degree from Dalhousie University in Halifax, interned at St. Paul’s Hospital in Vancouver, returned to complete specialty training in Diagnostic Imaging at Dalhousie University, and completed subspecialty training in Interventional Radiology at the Royal Melbourne Hospital in Australia. He returned to Dalhousie as Attending Staff and is now Full Clinical Professor at the Medical School.
Bob has a track record of licensed catheter innovations, granted patents, and is actively engaged in funded research projects with funding to date totaling more than $4 million. He established the IWK Uterine Fibroid Embolization (UFE) program in 2001 and the QEII Y-90 Radioembolization program in 2013. Dr. Abraham’s primary clinical expertise and research interests are in bland embolization, Y90 Radioembolization, Chemoembolization, Arterial and Venous Angioplasty / Intravascular Stenting, and endovascular treatment of complex thoracic and abdominal aortic aneurysms (Fenestrated and Branched Stent Graft Deployment). He is a recognized leader in Canada and has served as Chair of the Royal College of Physicians and Surgeons of Canada Examination in Diagnostic Radiology and as President of the Canadian Association for Interventional Radiology (CAIR/CIRA). He is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) and is certified with the American Board of Radiology.
Bob was honored as a Fellow of the Society of Interventional Radiology (FSIR) in 2016 and the Cardiovascular and Interventional Radiological Society of Europe (FCIRSE) in 2019 for his outstanding contributions and achievements in Interventional Radiology.
Dr. Abraham is a co-founder of ABK Biomedical Inc. and served as CEO from 2013-2018 developing the operational infrastructure and building the team to support the current R&D and manufacturing facilities.
Vice President, Manufacturing and Facilities
Anthony Headley is an accomplished medical device executive with 25 years experience leading and building engineering, manufacturing, operations and R&D organizations for multi-national and start-up medical device companies including Symbiosis, Boston Scientific, Enpath Medical, Kimberly-Clark Healthcare, and Hollister Incorporated. He has held positions of increasing responsibility including Director, Sr. Director, Vice-President and General Manager during his career.
He began his medical device career with Symbiosis Corporation (now Boston Scientific) where he quickly advanced into leadership positions in engineering and operations. He later relocated to Boston to lead the R&D stent development organization for Boston Scientific – Endoscopy where his team developed and introduced a number of market leading stent technologies. Before joining the ABK Biomedical Leadership Team, Anthony led the engineering organization for Hollister Incorporated where he managed a global team located in the US, Europe and Asia. Anthony is a licensed professional engineer and has been issued 26 US patents for medical device technologies during his career.
Halifax Office (Main Office)
155 Chain Lake Drive
Halifax, NS B3S 1B3
Orange County Office
555 Corporate Drive
Ladera Ranch, CA, 92694
ABK Biomedical Inc. provides and continues to provide accurate information on it's website. However, ABK Biomedical Inc. assumes no responsibility for accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical may change the products mentioned at any time without notice. ABK Biomedical Inc. is a Pre-clinical stage company engaged in the active research and development of new medical devices. ABK Biomedical products are considered investigational products and are NOT FDA approved for use. Y90 radioembolization
(C) Copyright 2021 - All International Rights Reserved